Comments on "Pharmacological Characterization of Apraglutide a Novel Long-Acting Peptidic Glucagon-Like Peptide-2 Agonist for the Treatment of Short Bowel Syndrome"

J Pharmacol Exp Ther. 2021 Jun;377(3):369. doi: 10.1124/jpet.120.000426.
No abstract available

Publication types

  • Letter
  • Comment

MeSH terms

  • Glucagon
  • Glucagon-Like Peptide 2
  • Humans
  • Peptides
  • Short Bowel Syndrome* / drug therapy

Substances

  • Glucagon-Like Peptide 2
  • Peptides
  • Glucagon
  • apraglutide